Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
ViiV’s HIV Drug Juluca Now Available in Japan
ViiV Healthcare launched its HIV combo treatment Juluca (dolutegravir + rilpivirine) in Japan on December 20, with GlaxoSmithKline being responsible for its distribution and marketing - as with other products developed through the tripartite joint venture of GSK, Pfizer, and…
To read the full story
Related Article
- ViiV’s HIV Drug Juluca to Join NHI Price List on Dec. 12
December 5, 2018
- HIV Drug Juluca Gets Japan Approval: ViiV
November 27, 2018
BUSINESS
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Takeda Files Entyvio IV for Pediatric Use, New Adult Dosing in Japan
July 29, 2026
- Japan OTC Market Falls for 4th Straight Month in June: Intage
July 29, 2026
- J-TEC, OSferionBiomaterials Join Forces to Expand Knee OA Business
July 29, 2026
- FunPep Allergy Vaccine Misses Exploratory Efficacy Goals in PI
July 29, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…